Haematologica Reports 2005; 1(issue 11):
11-13[prev][index][next]
The Intergroupe Francophone du Myélome experience
with thalidomide
Jean-Luc Harousseau,1 Michel Attal,2 Thierry
Facon,3 Ibrahim Yakoub-Agha2
1 University Hospital, Ch Hotel Dieu,1 place Alexis
Ricordeau BP 1005, 44093 Nantes, France.
Phone: +33.240083271 E-mail: jlharousseau@sante.univ-nantes.fr
2 University Hospital,Toulouse; 3University
Hospital Lille, France
The Intergroupe Francophone du Myélome (IFM) has conducted
studies of thalidomide as treatment for relapsed or refractory
multiple myeloma (MM) and as first-line therapy. One study
comparing two doses of thalidomide (100 vs 400 mg/d) in relapsed
patients has not yet been analyzed. Another study testing low-dose
thalidomide in combination with melphalan and prednisone (MP) in
elderly patients (>75 years) with newly diagnosed MM is ongoing.
Three studies are presented here. Of these, one phase 2 study in
relapsed/refractory patients has already been published; the other
two have been presented in meetings only. [>Read full article in PDF]
